Published in Vaccine Weekly, October 20th, 2004
According to published research from the United States, "Mice immunized with respiratory syncytial virus G glycoprotein or with formalin-inactivated RSV (FI-RSV) exhibit severe disease following RSV challenge. This results in type 2 cytokine production and pulmonary eosinophilia, both hallmarks of vaccine-enhanced disease. RSV G-induced T-cell responses were shown to be restricted to CD4+ T cells expressing Vbeta14 in the T-cell receptor (TCR), and the deletion of these T cells resulted in less...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly